Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma

Abstract Activating point mutations in Anaplastic Lymphoma Kinase (ALK) have positioned ALK as the only mutated oncogene tractable for targeted therapy in neuroblastoma. Cells with these mutations respond to lorlatinib in pre-clinical studies, providing the rationale for a first-in-child Phase 1 tri...

Full description

Bibliographic Details
Main Authors: Esther R. Berko, Gabriela M. Witek, Smita Matkar, Zaritza O. Petrova, Megan A. Wu, Courtney M. Smith, Alex Daniels, Joshua Kalna, Annie Kennedy, Ivan Gostuski, Colleen Casey, Kateryna Krytska, Mark Gerelus, Dean Pavlick, Susan Ghazarian, Julie R. Park, Araz Marachelian, John M. Maris, Kelly C. Goldsmith, Ravi Radhakrishnan, Mark A. Lemmon, Yaël P. Mossé
Format: Article
Language:English
Published: Nature Portfolio 2023-05-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-38195-0

Internet

https://doi.org/10.1038/s41467-023-38195-0

Similar Items